Sun Pharma approves INR 100.00 billion debt issue: what it means for Sun Pharma stock

Published on 10/13/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Board approved INR 100.00 billion debentures on October 12, 2026. For Sun Pharma stock, Q1 fiscal 2027 revenue rose 10.10 percent to INR 153.0 billion.

Sun Pharma's board approved INR 100.00 billion of non-convertible debentures on October 12, 2026.
The financing decision follows Q1 fiscal 2027 revenue growth of 10.10 percent to INR 153.0 billion.
Domestic formulations grew 16.00 percent in Q1 fiscal 2027, while US sales declined 9.70 percent in constant currency.
Sun Pharma stock trades on the NSE under ticker SUNPHARMA and is included in the Nifty 50.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (INE044A01036) approved INR 100.00 billion of non-convertible debentures on October 12, 2026, adding a significant financing decision to the company's investment story. Sahi reported that the private placement will be issued in tranches, while independent director Gautam Doshi resigned with immediate effect on the same date.

What does the debt issue mean?

The board decision follows a proposal reported by Reuters on October 7, 2026, when Sun Pharma said it would consider up to INR 150.00 billion of non-convertible debentures at the October 12 board meeting. The approved INR 100.00 billion is therefore below the earlier maximum proposal.

For investors, the next measurable details are tranche pricing, maturity and coupon costs. Sahi identified those terms as the factors that will shape the funding impact, while also noting Sun Pharma's Baa1 rating from Moody's and BBB+ rating from S&P Global, both with stable outlooks.

Three milestones in twelve months

The latest event follows three quantified milestones. On May 7, 2026, Sun Pharma agreed to acquire Organon for an enterprise value of USD 11.75 billion, according to ScanX. On July 31, 2026, Q1 fiscal 2027 revenue reached INR 153.0 billion, up 10.10 percent year over year, while net profit reached INR 28.95 billion, as reported by DSIJ. The October 12 debenture approval is the current event in that sequence.

Dates investors can track

StockFin reported that results from Sun Pharma's postal ballot process are due by November 3, 2026. The vote covers seven special resolutions, including the 2026 employee stock option plan and changes to borrowing and investment limits.

Growth offsets part of the funding risk

Q1 fiscal 2027 supplied a stronger operating counterweight to the financing decision. Domestic formulations grew 16.00 percent to INR 54.7 billion, while global innovative-medicines sales increased 13.00 percent to USD 351.00 million, according to DSIJ.

The mix was uneven: US sales fell 9.70 percent in constant currency to USD 427.00 million, while EBITDA rose 4.00 percent year over year to INR 41.8 billion and the EBITDA margin declined to 27.50 percent. That contrast makes the debt decision a balance-sheet question as well as a growth question.

Funding terms set the next test

The October 12 approval gives Sun Pharma access to domestic debt financing, but the economic effect depends on the final coupon and maturity structure. The combination of a 10.10 percent Q1 revenue increase, 16.00 percent domestic growth and a 100.00 billion rupee borrowing authorization leaves those terms as the clearest next reference points for the stock.